Rick Jantz

Cooley advised X4 Pharmaceuticals in its exclusive license agreement with Abbisko Therapeutics granting Abbisko exclusive rights to develop and commercialize maxorixafor in combination with checkpoint inhibitors or other agents in oncology indications in China, Taiwan, Hong Kong and Macau.

Cooley advised GENFIT SA in its licensing and collaboration agreement with Terns Pharmaceuticals. Terns will have the rights to develop and commercialize elafibranor, GENFIT’s proprietary compound, in Greater China. Under the terms of the agreement, GENFIT received an upfront payment from Terns of $35 million and will be eligible to receive up to $193 million in potential clinical, regulatory and commercial milestone payments.

Cooley advised Vir Biotechnology on its $142.9 million initial public offering of 7,142,858 shares of common stock. Vir Biotechnology, whose securities now trade on Nasdaq Global Select Market under the symbol "VIR", is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Partners Laura Berezin, Charlie Kim and Kristin VanderPas led the Cooley team.

Cooley advised Arlo Technologies, the leading internet-connected camera brand, on its agreement to enter into a strategic partnership with Verisure Sàrl. Partners Barbara Borden, Tom Coll and Charles Haley led the Cooley team advising Arlo.

Cooley advised the underwriters on Reata Pharmaceuticals' $505 million follow-on offering of 2,760,000 shares of Class A common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. Citigroup, Jefferies, SVB Leerink and Stifel acted as the joint book-running managers for the offering. Cantor, Baird and Ladenburg Thalmann acted as co-managers for the offering. Partners Rich Segal, Div Gupta and Charlie Kim led the Cooley team.